The cost-effectiveness of harm reduction
Open Access
- 1 February 2015
- journal article
- research article
- Published by Elsevier in International Journal of Drug Policy
- Vol. 26, S5-S11
Abstract
No abstract availableKeywords
Funding Information
- Australian National Health and Medical Research Council
- World Bank Group
- Australian Government
This publication has 65 references indexed in Scilit:
- Prevention, treatment and care of hepatitis C virus infection among people who inject drugsInternational Journal of Drug Policy, 2015
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for UkrainePLOS Medicine, 2011
- HIV epidemics and prevention responses in Asia and Eastern Europe: lessons to be learned?AIDS, 2010
- Time to act: a call for comprehensive responses to HIV in people who use drugsThe Lancet, 2010
- Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysisAIDS, 2009
- Cost-Effectiveness of Needle and Syringe Exchange for the Prevention of HIV in New York CityJournal of HIV/AIDS & Social Services, 2008
- Evaluating effectiveness of syringe exchange programmes: current issues and future prospectsSocial Science & Medicine, 2000
- Risk factors and HIV seropositivity among injecting drug users in BangkokAIDS, 1991